THE APPLICATION OF THE NATIONAL INSTITUTE OF CLINICAL EXCELLENCE GUIDELINES FOR TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN THE UNITED KINGDOM: FRIEND OR FOE?

In this article the author discusses the use of targeted therapy as a replacement for immunotherapy in treating patients with metastatic renal cell carcinoma (mRCC) in Great Britain. The author states that the National Institute of Clinical Excellence (NICE) is considering the cost and effectiveness of the drug. Also mentioned are the clinical issues such as the commencement and discontinuity of using the therapy and how to treat patients who are not qualified for sunitinib.